Ogunkelu J B, Damato A N, Akhtar M, Reddy C P, Caracta A R, Lau S H
Am J Cardiol. 1976 Apr;37(5):724-31. doi: 10.1016/0002-9149(76)90366-0.
The effects of single intravenous infusions of 50 to 400 mg of procainamide on the functional properties of the atrioventricular (A-V) conduction system were studied in 36 patients and correlated with plasma concentrations. A 50 mg dose of procainamide resulted in a plasma concentration of less than 1.0 mug/ml and produced no electrophysiologic changes. Doses of 100, 200, 300 and 400 mg resulted in progresively increasing plasma concentrations (1.2, 1.8, 3.5 and 4.2 mug/ml, respectively). The effects of procainamide on the sinus rate were variable and not dose-related. The effects of doses of up to 300 mg on A-V nodal conduction were variable and not dose-related. Only in a dose of 400 mg did procainamide prolong A-V nodal conduction in six of seven patients. Whereas 100 mg had no effect on His-Purkinje system conduction, doses of 200, 300 and 400 mg prolonged His-Purkinje system conduction time by 6, 8 and 9 msec, respectively. Dose-related increases in atrial refractoriness started with a dose of 200 mg and became statistically significant with doses of 300 and 400 mg. The effects of procainamide on A-V nodal functional refractoriness were variable and not dose-related, but in doses of 100 to 400 mg, procainamide produced significant and progressively dose-related increases in His-Purkinje system refractoriness. Suppression of some types of ventricular arrhythmia by small doses of this drug may be explained by changes in refractoriness of the His-Purkinje system produced by doses of procainamide as small as 100 mg.
在36例患者中研究了单次静脉输注50至400毫克普鲁卡因胺对房室(A-V)传导系统功能特性的影响,并与血浆浓度进行了相关性分析。50毫克剂量的普鲁卡因胺导致血浆浓度低于1.0微克/毫升,未产生电生理变化。100、200、300和400毫克剂量导致血浆浓度逐渐升高(分别为1.2、1.8、3.5和4.2微克/毫升)。普鲁卡因胺对窦性心率的影响是可变的,且与剂量无关。高达300毫克剂量对A-V结传导的影响是可变的,且与剂量无关。仅在400毫克剂量时,普鲁卡因胺使7例患者中的6例A-V结传导延长。100毫克对希氏-浦肯野系统传导无影响,而200、300和400毫克剂量分别使希氏-浦肯野系统传导时间延长6、8和9毫秒。心房不应期与剂量相关的增加始于200毫克剂量,在300和400毫克剂量时具有统计学意义。普鲁卡因胺对A-V结功能不应期的影响是可变的,且与剂量无关,但在100至400毫克剂量时,普鲁卡因胺使希氏-浦肯野系统不应期显著增加且与剂量相关。小剂量该药物对某些类型室性心律失常的抑制作用可能是由于小至100毫克剂量的普鲁卡因胺引起的希氏-浦肯野系统不应期变化所致。